Top Companies and Their Offerings
| Companies | Headquarters | Veterinary Regenerative Medicines |
| Zoetis Inc. | Parsippany, U.S. | Pro-stride APS and Restigen PRP |
| Vetherapy | Miami, U.S. | Hypo-Stem |
| VetStem, Inc. | Poway, U.S. | VetStem Cell Therapy and Steminsure |
| Animal Cell Therapies | San Diego, U.S. | ACT Canine Stem Cell Therapy |
| Boehringer Ingelheim | Ingelheim, Germany | Arti-Cell Forte and RenuTend |
| Vetbiologics | Olean, U.S. | V-Pet and BMAC kits |
| Dechra Pharmaceuticals | Northwich, UK | Orthokine vet irap and Osteokine PRP |
| Medrego | Riga, Latvia | CaniCell and EquiCell |
| Ardent Animal Health | Lexington, U.S. | Ardent Stem Cell Therapy and PurePRP |
| Enso Discoveries | Manhattan, U.S. | Rebound PRP and Rebond PRF |
Veterinary Regenerative Medicine Market Value Chain Analysis
R&D
- The R&D of veterinary regenerative medicine focuses on the development of allogenic “off-the-shelf” stem cell products and standardized biotherapeutics.
- Key players: Zoetis Inc., VetStem, Inc., Boehringer Ingelheim.
Clinical Trials and Regulatory Approvals
- The safety, toxicology, manufacturing consistency, and clinical efficacy are evaluated in the clinical trials and regulatory approvals of the veterinary regenerative medicine.
- Key players: Zoetis Inc., VetStem, Inc., Boehringer Ingelheim.
Patient Support and Services
- Pet owner education portals, specialized training, and long-term cell banking are provided in the patient support and services of the veterinary regenerative medicine.
- Key players: Zoetis Inc., VetStem, Inc., Ardent Animal Health.
What are the Recent Developments in the Veterinary Regenerative Medicine Market?
- In November 2025, to address major unmet needs in animal health, RION, which is a clinical-stage regenerative medicine company, announced the launch of RION Vet, a veterinary biotechnology company. The company will focus on the first-in-class platelet-derived biologic therapeutic, where its first product (ePEP-01) is a cell-free, shelf-stable biologic derived from platelets for equine musculoskeletal indications.
- In June 2025, a successful closing of a $18 million Series B financing round was announced by Gallant, which is an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets. The company will focus on regenerative medicines, where it will introduce a new category in veterinary care by offering ready-to-use stem cell therapies for the most common and underserved diseases of cats and dogs.
Market Growth
The global veterinary regenerative medicine market size was estimated at USD 1.42 billion in 2025 and is predicted to increase from USD 1.6 billion in 2026 to approximately USD 4.74 billion by 2035, expanding at a CAGR of 12.8% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking